Acquisition upside ViS Research was acquired by IQVIA, indicating potential cross-sell opportunities for IQVIA’s broader CRO and data analytics capabilities to existing ViS clients and to leverage IQVIA's global footprint.

Feasibility platform value The online feasibility platform reduces time and cost for trial planning by providing location, site, and investigator engagement in one place, suggesting opportunities to upsell expanded analytics, site optimization, and trial master planning services.

Global network leverage ViS maps global clinical research infrastructure and enables direct engagement with centers, creating a selling point for IQVIA to extend network-based solutions, data services, and site performance analytics across geographies.

Center enablement Research centers can build online profiles answering the majority of feasibility questions, presenting a recurring engagement channel for platform monetization, data enrichment services, and premium listings or profiling.

Market positioning Operating in IT services and clinical trial optimization with modest headcount and mid-market revenue range, ViS/ IQVIA combination can target mid-tier pharma and biotech clients seeking cost-efficient trial setup and faster site activation.